BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31918331)

  • 1. The Clinical Management and Outcomes of Pelvic Neuroblastic Tumors.
    Zobel M; Zamora A; Sura A; Wang L; Stein J; Marachelian A; Kim ES
    J Surg Res; 2020 May; 249():8-12. PubMed ID: 31918331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical management and outcomes of cervical neuroblastic tumors.
    Jackson JR; Tran HC; Stein JE; Shimada H; Patel AM; Marachelian A; Kim ES
    J Surg Res; 2016 Jul; 204(1):109-13. PubMed ID: 27451875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pelvic neuroblastoma: low mortality and high morbidity.
    Cruccetti A; Kiely EM; Spitz L; Drake DP; Pritchard J; Pierro A
    J Pediatr Surg; 2000 May; 35(5):724-8. PubMed ID: 10813335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection.
    Irtan S; Brisse HJ; Minard-Colin V; Schleiermacher G; Galmiche-Rolland L; Le Cossec C; Elie C; Canale S; Michon J; Valteau-Couanet D; Sarnacki S
    Pediatr Blood Cancer; 2015 Sep; 62(9):1543-9. PubMed ID: 25820608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroblastoma: treatment outcome after incomplete resection of primary tumors.
    Moon SB; Park KW; Jung SE; Youn WJ
    Pediatr Surg Int; 2009 Sep; 25(9):789-93. PubMed ID: 19629500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized pelvic neuroblastoma: excellent survival and low morbidity with tailored therapy--the 10-year experience of the French Society of Pediatric Oncology.
    Leclair MD; Hartmann O; Heloury Y; Fourcade L; Laprie A; Mechinaud F; Munzer C; Rubie H
    J Clin Oncol; 2004 May; 22(9):1689-95. PubMed ID: 15117991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localized dumbbell neuroblastoma: a study of 25 cases treated between 1982 and 1987 using the same protocol.
    Plantaz D; Hartmann O; Kalifa C; Sainte-Rose C; Lemoine G; Lemerle J
    Med Pediatr Oncol; 1993; 21(4):249-53. PubMed ID: 8469218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of surgery in the treatment of patients with high-risk neuroblastoma who have a poor response to induction chemotherapy.
    Du L; Liu L; Zhang C; Cai W; Wu Y; Wang J; Lv F
    J Pediatr Surg; 2014 Apr; 49(4):528-33. PubMed ID: 24726106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.
    Holmes K; Pötschger U; Pearson ADJ; Sarnacki S; Cecchetto G; Gomez-Chacon J; Squire R; Freud E; Bysiek A; Matthyssens LE; Metzelder M; Monclair T; Stenman J; Rygl M; Rasmussen L; Joseph JM; Irtan S; Avanzini S; Godzinski J; Björnland K; Elliott M; Luksch R; Castel V; Ash S; Balwierz W; Laureys G; Ruud E; Papadakis V; Malis J; Owens C; Schroeder H; Beck-Popovic M; Trahair T; Forjaz de Lacerda A; Ambros PF; Gaze MN; McHugh K; Valteau-Couanet D; Ladenstein RL;
    J Clin Oncol; 2020 Sep; 38(25):2902-2915. PubMed ID: 32639845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic neuroblastoma--implications for a new favorable subgroup: a Children's Cancer Group experience.
    Haase GM; O'Leary MC; Stram DO; Lukens JN; Seeger RC; Shimada H; Matthay KK
    Ann Surg Oncol; 1995 Nov; 2(6):516-23. PubMed ID: 8591082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.
    Yanishevski D; McCarville MB; Doubrovin M; Spiegl HR; Zhao X; Lu Z; Federico SM; Furman WL; Murphy AJ; Davidoff AM
    J Pediatr Surg; 2020 Jan; 55(1):130-134. PubMed ID: 31685267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
    Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
    Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comprehensive treatment of neuroblastoma in children associated with opsoclonus-myoclonus-ataxia syndrome].
    Zhao W; Sun Q; Xie Y; Hua Y; Xiong H; Jia J; Lu X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):540-3. PubMed ID: 25224062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of Image-Defined Risk Factors for the Extent of Surgical Resection and Clinical Outcome in Patients with Pelvic Neuroblastoma.
    Froeba-Pohl A; von Schweinitz D; Muehling J; Paolini M; Hubertus J
    Eur J Pediatr Surg; 2021 Aug; 31(4):362-366. PubMed ID: 32862422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic large cell neuroblastoma.
    Abramowsky CR; Katzenstein HM; Alvarado CS; Shehata BM
    Pediatr Dev Pathol; 2009; 12(1):1-5. PubMed ID: 18397155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience.
    McGregor LM; Rao BN; Davidoff AM; Billups CA; Hongeng S; Santana VM; Hill DA; Fuller C; Furman WL
    Cancer; 2005 Dec; 104(12):2837-46. PubMed ID: 16288490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete resection is not required in patients with neuroblastoma under 1 year of age.
    Kaneko M; Iwakawa M; Ikebukuro K; Ohkawa H
    J Pediatr Surg; 1998 Nov; 33(11):1690-4. PubMed ID: 9856897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.